Literature DB >> 12970571

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta.

Chih-Hao Lee1, Ajay Chawla, Ned Urbiztondo, Debbie Liao, William A Boisvert, Ronald M Evans, Linda K Curtiss.   

Abstract

The formation of an atherosclerotic lesion is mediated by lipid-laden macrophages (foam cells), which also establish chronic inflammation associated with lesion progression. The peroxisome proliferator-activated receptor (PPAR) gamma promotes lipid uptake and efflux in these atherogenic cells. In contrast, we found that the closely related receptor PPARdelta controls the inflammatory status of the macrophage. Deletion of PPARdelta from foam cells increased the availability of inflammatory suppressors, which in turn reduced atherosclerotic lesion area by more than 50%. We propose an unconventional ligand-dependent transcriptional pathway in which PPARdelta controls an inflammatory switch through its association and disassociation with transcriptional repressors. PPARdelta and its ligands may thus serve as therapeutic targets to attenuate inflammation and slow the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970571     DOI: 10.1126/science.1087344

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  182 in total

1.  PPARδ coordinates angiotensin II-induced senescence in vascular smooth muscle cells through PTEN-mediated inhibition of superoxide generation.

Authors:  Hyo Jung Kim; Sun Ah Ham; Min Young Kim; Jung Seok Hwang; Hanna Lee; Eun Sil Kang; Taesik Yoo; Im Sun Woo; Chihiro Yabe-Nishimura; Kyung Shin Paek; Jin-Hoi Kim; Han Geuk Seo
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 3.  Vascular effects of prostacyclin: does activation of PPARδ play a role?

Authors:  Zvonimir S Katusic; Anantha V Santhanam; Tongrong He
Journal:  Trends Pharmacol Sci       Date:  2012-06-23       Impact factor: 14.819

Review 4.  Control of macrophage activation and function by PPARs.

Authors:  Ajay Chawla
Journal:  Circ Res       Date:  2010-05-28       Impact factor: 17.367

5.  Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.

Authors:  Ding Ai; Hongfeng Jiang; Marit Westerterp; Andrew J Murphy; Mi Wang; Anjali Ganda; Sandra Abramowicz; Carrie Welch; Felicidad Almazan; Yi Zhu; Yury I Miller; Alan R Tall
Journal:  Circ Res       Date:  2014-03-31       Impact factor: 17.367

6.  AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.

Authors:  Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

7.  PPARs in atherosclerosis: the clot thickens.

Authors:  Antonio Castrillo; Peter Tontonoz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

8.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 9.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

10.  Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages.

Authors:  Xinbing Han; Shiro Kitamoto; Qingyu Lian; William A Boisvert
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.